Auriga Maintains a 'Hold' on ViroPharma (VPHM); Generic Competition in Vancocin
Get Alerts VPHM Hot Sheet
Price: $49.96 --0%
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Rating Summary:
5 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Auriga maintains a 'Hold' on ViroPharma (NASDAQ: VPHM) price target of $19.00.
Analyst, Difei Yang, said, "Three generic Vancocin products were granted FDA approvals yesterday and at least two are shipping products. We do not expect Viropharma's request for preliminary injunction to be granted and thus expect full blown generic erosion to the Vancocin business immediately. We expect high volatility of the share price over the next few weeks as legal actions play out and we would advise our clients to stay on the sidelines."
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
Analyst, Difei Yang, said, "Three generic Vancocin products were granted FDA approvals yesterday and at least two are shipping products. We do not expect Viropharma's request for preliminary injunction to be granted and thus expect full blown generic erosion to the Vancocin business immediately. We expect high volatility of the share price over the next few weeks as legal actions play out and we would advise our clients to stay on the sidelines."
For an analyst ratings summary and ratings history on ViroPharma click here. For more ratings news on ViroPharma click here.
Shares of ViroPharma closed at $22.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Arch Coal (ARCH) to Neutral
- Travelers (TRV) PT Lowered to $214 at Morgan Stanley
- UBS Reiterates Sell Rating on Beiersdorf AG (BEI:GR) (BDRFY)
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!